Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation

Quadruplet induction, autologous hematopoietic cell transplant (AHCT), and measurable residual disease (MRD) response‐adapted consolidation yield an unprecedented depth of response in newly diagnosed multiple myeloma. Patients treated on MASTER (NCT03224507) ceased therapy and entered active surveil...

Descripción completa

Detalles Bibliográficos
Autores principales: Silbermann, Rebecca W., Schmidt, Timothy Martin, Bal, Susan, Dhakal, Binod, Dholaria, Bhagirathbhai, Biltibo, Eden, Chhabra, Saurabh, Giri, Smith, Godby, Kelly N., Gowda, Sonia, Medvedova, Eva, Cornell, Robert F., Callander, Natalie S., Costa, Luciano J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435700/
https://www.ncbi.nlm.nih.gov/pubmed/37601885
http://dx.doi.org/10.1002/jha2.736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435700/
https://www.ncbi.nlm.nih.gov/pubmed/37601885
http://dx.doi.org/10.1002/jha2.736

Ejemplares similares